Making the case for a microbiome-based personalized diet

Chosen from a record number of submissions, the company’s latest study compares a microbiome-based artificial intelligence-assisted personalized diet and a commonly administered diet in patients with irritable bowel syndrome (IBS). 

“As you know, the low FODMAP diet is a symptoms-based approach, mainly engineered to treat the bloating and the pain that IBS patients suffer but doesn’t take into account the microbiome of the patient,” Dr. Varol Tunali, medical director at Enbiosis, said. “Our first outcome is to take the microbiome to a better state, and then symptom relief is the result of this microbiome improvement.”  

Personalized diet vs. low FODMAP diet 

For its investigation, Enbiosis evaluated various subjective physical and psychological indices in 41 IBS patients who followed either a personalized diet (PD) or a low FODMAP diet (LFD) for six weeks. Gut microbiome composition as determined by fecal analysis provided an objective measure. 

“The personalized diet showed superiority over the low FODMAP diet in 7 out of 11 indices,” Dr. Tunali said. “Although the difference was not statistically significant, the performance of the personalized diet was consistently better compared to the low FODMAP diet.”

In addition, PD promoted alpha and beta diversity in the gut microbial composition, while the lack of substantial diversity shifts in the PD group suggested longer-term consequences of a restrictive diet beyond symptom relief.

“The most significant finding, in my perspective, is that the personalized diet showed improvement in the quality of life for all subgroups of IBS,” Dr. Tunali said. “In contrast, the low FODMAP diet only demonstrated such improvements for IBS-Constipation. This finding is particularly significant as it emphasizes personalization’s crucial role in addressing diverse needs even within the same syndrome.”

Source link